Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab Augmentation in Depression
NCT04531423Unknown
- Sponsor
- Shanghai Mental Health Center
- Start
- Oct 2020
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
01
Overview
Randomised, double-blind trial in major depressive disorder (MDD) comparing SSRI + Golimumab with SSRI + Placebo (2 arms). Primary endpoint: remission of acute phase at 12 weeks. Status: unknown.
02
Drugs
golimumab
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04531423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04531423.